



11February 2013
Company Announcements Office
Australian Stock Exchange
Level 6, 20 Bridge Street
Sydney NSW 2000

NEWSLETTER

Dear Shareholders,

I am giving a presentation at the BIO Investor Conference in New York 11 February 2013 (NAET).
The following slides will form the basis of the presentation.

Dr Geoff Cumming
CEO
Anteo Diagnostics Limited

Anteo Diagnostics Limited ABN 78 090 487 273
Unit 4, 26 Brandl Street, Eight Mile Plains Qld 4113

Phone 07 3219 0085 **Fax** 07 3219 0553 **Email** contact@anteodx.com **Web** www.anteodx.com

Mix&Go™ – Binding Biomolecules Better (And Easier)

BIO Investor Conference
New York, February 11, 2013
Geoff Cumming, CEO, Anteo Diagnostics



Forward Looking Statement

The purpose of the presentation is to provide an update of the business of Anteo Diagnostics (ASX:ADO). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Anteo and should not be relied upon as an independent source of information. Please contact Anteo and/or refer to the Company's website for further information.

The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information.

Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Anteo Diagnostics Ltd's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and Anteo's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution.

This presentation should not be relied on as a recommendation or forecast by Anteo Diagnostics Limited. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.



Anteo Diagnostics Overview

Facts at a Glance

Listed on the ASX (Australian Securities Exchange), code: ADO

Market Capitalisation: A\$50m

52 week high: 9 cents

52 week low: 5 cents, currently 6.6 cents

Shares on Issue: 772,851,591

Shareholders: 3,449

Average Daily Volume: 518,392 (past 30 days)

Top 20: Hold 35.76% issued capital

Directors/Staff: 17.8%

Business Model

Revenues from product sales, royalties and research and collaboration agreements with diagnostic and other life sciences companies

Proven Technology Platform

Proprietary technology licensed to major international players with additional deals anticipated

Patented Technology

Significant and growing patent portfolio

Robust Deal Portfolio

Over 80 of the major global names in several distinct markets and market segments are actively assessing our process in-house

Strong Leadership

Board and management has proven track record of developing successful companies and products

Strong Balance Sheet

\$4.2 million of cash gives us runway into calendar 2014 on current burn rate

Who Wins?

Laboratory Diagnostics Immunoassays



- Global IVD: \$44B (2011)
- Immunoassays: \$8.8B (2015 forecast)
- Drivers: aging population = more tests, higher Asian demand, technology innovations

Point-of-Care



- \$8 B (2011)
- \$38B (2017 forecast)
- Drivers: price pressure, lack of qualified staff, need for immediate information, decentralization, bedside testing

Rapid Test Products



- \$3.7B in 2012
- Drivers: decentralized testing, broadening applications, direct to consumer marketing


Novel Diagnostic Systems



- Examples: multiplexed systems, novel label-free detection
- Drivers: economic – more data per test, cheaper, novel biomarkers



Mix&Go Solution




Better protein attachment means

- Better, more sensitive diagnostic tests
- Lower cost tests
- Faster test development times
- Novel, technically difficult tests can be developed



The Magic: “Molecular Velcro”



- Clusters on metal ions
- Double-sided “molecular Velcro”
- Binds to almost all surfaces
- Binding strong yet gentle
- Simple formulation
- Easy and cheap to manufacture
- Very stable



“I should have thought of that! It’s brilliant in its simplicity”

- Principal Scientist at large international life science tools provider

“Mix&Go is so easy to use, it’s surface chemistry without the chemistry!”

- Senior Scientist at top 5 IVD company





Business Model

Model	Characteristics
<p style="text-align: center;">Licensing</p> <ul style="list-style-type: none"> • Technology Access Fee • Milestone Payments • Royalties • Royalties on sub-licensee sales 	<ul style="list-style-type: none"> • Predictable, long-term revenue stream • Little direct competition • Focus on business development, key account management • Limited sales and marketing required
<p style="text-align: center;">Sales</p> <ul style="list-style-type: none"> • Direct and/or through 3rd parties • Stand-alone or bundled with reseller's product/system 	<ul style="list-style-type: none"> • Faster source of smaller revenues • Sales to well-defined market segments with proven need • Ability to serve market segments otherwise difficult to reach, e.g. academic users
<p style="text-align: center;">R&D Collaboration</p> <ul style="list-style-type: none"> • FTE reimbursement • Joint product development → licensing 	<ul style="list-style-type: none"> • Source of limited short term revenues • Main purpose: support licensing activities when more customization is needed • Used to develop optimal processes



Team

Executive Team



Dr. Geoff Cumming, CEO



Dr. Joe Maeji, CSO



**Dr. Tina Baumgartner,
VP Business Development & Marketing**

Board of Directors



**Dr. Mark Bouris,
Chairman**



**Dr. Geoff Cumming
Managing Director**



**Sam Anderson
Non-Executive Director**



**Richard Martin
Executive Director**



**New Board member
(TBA)**

Contact Information

Thank you very much for your interest in Anteo Diagnostics
For more information please contact:

